.Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AL02_SalbutamolAndIpratropium.SalbutamolAndIpratropium .Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AL02_SalbutamolAndIpratropium.SalbutamolAndIpratropium| name: | SalbutamolAndIpratropiumBromide |
| ATC code: | R03AL02 | route: | inhalation |
| n-compartments | 1 |
Fixed-dose combination of salbutamol (a short-acting beta2-adrenergic agonist) and ipratropium bromide (a short-acting muscarinic antagonist) used primarily as a bronchodilator in the management of chronic obstructive pulmonary disease (COPD) and sometimes asthma. The combination is approved and widely used today in inhalation formulations for rapid symptomatic relief.
Estimated pharmacokinetic parameters for typical adult population, based on published PK data for separate components (inhaled salbutamol, inhaled ipratropium bromide); no published population PK studies available for the fixed combination product.
MacGregor, TR, et al., & Wood, CC (2016). Efficiency of Ipratropium Bromide and Albuterol Deposition in the Lung Delivered via a Soft Mist Inhaler or Chlorofluorocarbon Metered-Dose Inhaler. Clinical and translational science 9(2) 105–113. DOI:10.1111/cts.12387 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26945929
Antoniu, S (2014). Bedoradrine for treating asthma and chronic obstructive pulmonary disease. Expert opinion on investigational drugs 23(8) 1149–1156. DOI:10.1517/13543784.2014.928284 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24938936